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A Mouse Model for Evaluation of Prophylaxis and Therapy of Ebola
Hemorrhagic Fever
Mike Bray, Kelly Davis, Tom Geisbert,
Connie Schmaljohn, and John Huggins

Divisions of Virology and Pathology, US Army Medical Research
Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland

The Zaire subtype of Ebola virus (EBO-Z) is lethal for newborn mice, but adult mice are resistant
to the virus, which prevents their use as an animal model of lethal Ebola infection. We serially
passed EBO-Z virus in progressively older suckling mice, eventually obtaining a plaque-purified
virus that was lethal for mature, immunocompetent BALB/c and C57BL/6 inbred and ICR (CD-1)
outbred mice. Pathologic changes in the liver and spleen of infected mice resembled those in EBOZ – infected primates. Virus titers in these tissues reached 109 pfu/g. The LD50 of mouse-adapted
EBO-Z virus inoculated into the peritoneal cavity was Ç1 virion. Mice were resistant to large
doses of the same virus inoculated subcutaneously, intradermally, or intramuscularly. Mice injected
peripherally with mouse-adapted or intraperitoneally with non-adapted EBO-Z virus resisted subsequent challenge with mouse-adapted virus.

Infection with Ebola (EBO) virus, subtype Zaire (EBO-Z),
produces severe or fatal illness in nonhuman primates, guinea
pigs, and suckling mice [1]. The virus causes lethal hemorrhagic fever in rhesus and cynomolgus macaques (Macaca rhesus and Macaca fascicularis), African green monkeys (Cercopithecus aethiops), and baboons (Papio hamadryas) [2 – 5]. It
replicates to high titers in the liver, spleen, lymph nodes, and
other organs, causing tissue necrosis, hemorrhage, and shock
[6 – 8]. Cells of the mononuclear phagocytic system (MPS) are
major targets of infection [8]. Hepatocytes, endothelial cells,
and other cell types are also infected.
Guinea pigs inoculated with infectious material from human
EBO-Z cases develop a nonlethal febrile illness [9, 10]. Sequential passage from animal to animal of virus in splenic
homogenates results in a progressive increase in virulence,
soon reaching uniform lethality [3]. Connolly et al. [11] (this
supplement) recently provided quantitative data on the adaptation process: They compared the level of viremia induced by
non-adapted EBO-Z in strain 13 guinea pigs with that produced
by virus from each of 4 sequential passages. The mean serum
virus titer 7 days after infection increased from 101.2 to 105.2
pfu/mL, paralleling an increase from 20% to 100% in the lethal-
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ity of the virus. Another report of histologic changes associated
with increasing virulence during sequential passage in outbred
guinea pigs found that the virus was fatal for some animals
after 3 passages, and its lethality increased through 4 additional
passages [12]. In passages 1 – 3, viral replication was observed
only in small numbers of MPS cells, including Kupffer’s cells
of the liver. Virus titers in the tissues were very low. Beginning
with the fourth passage, there was increasing infection of MPS
cells, hepatocytes, and endothelial cells.
Intraperitoneal (ip) or intracerebral (ic) inoculation of EBOZ causes lethal infection in newborn mice [13, 14]. Smaller
quantities of virus can be detected by titration in newborn mice
than by plaquing in tissue culture: Ryabchikova et al. [10]
reported that a 0.1-pfu ic dose of EBO-Z was lethal for 50%
of mice. Only very young suckling mice are sensitive to EBO
infection [14]. However, EBO-Z was also lethal for adult SCID
BALB/c mice, in which the virus replicated to high titers in
liver, spleen, and other tissues (Huggins J, unpublished data).
EBO infection in SCID mice followed a very different course
from that in the above-mentioned animals: While monkeys,
guinea pigs, and suckling mice became acutely ill 4 – 6 days
after inoculation of EBO-Z and died 6 – 11 days after infection,
SCID mice developed gradual, progressive weight loss and
slowing of activity and died 20 – 25 days after challenge.
There are no approved EBO vaccines and no therapeutic
measures of proven efficacy. There is an urgent need for a
model of EBO infection in immunocompetent adult mice in
order to accelerate the pace of vaccine development and to
make it possible to evaluate limited quantities of experimental
antiviral drugs in animals smaller than guinea pigs. We therefore decided to attempt the adaptation of EBO-Z to adult mice
of the common BALB/c inbred laboratory strain.
Materials and Methods
Biologic containment. Infectious material and animals were
handled in maximum-containment biosafety level 4 facilities at
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the United States Army Medical Research Institute of Infectious
Diseases (USAMRIID). Laboratory personnel wore positive-pressure protective suits (ILC Dover, Frederica, DE) equipped with
high-efficiency particulate air filters and supplied with umbilicalfed air.
Virus and cells. The 1976 strain (Mayinga) of EBO-Z virus
(passed either once in Vero cells or three times ic in suckling mice
and then once in Vero cells [15]) and the 1995 strain of EBO-Z
virus (passed twice in Vero cells) were provided by Peter Jahrling
(USAMRIID). The viruses were amplified in Vero E6 cells, and
the supernatant was collected to produce stocks of EBO-Z ’76
Vp2, EBO-Z ’76 Mp3 Vp2, and EBO-Z ’95 Vp3. The E6 line of
Vero African green monkey kidney cells (Vero C1008, ATCC
CRL 1586) was propagated in modified Eagle medium (MEM)
with Earle’s balanced salts, nonessential amino acids, 10% fetal
bovine serum (FBS), glutamine, penicillin, and streptomycin; the
same medium with 2% FBS was used as replacement medium
after cells were infected.
Titration by plaquing and by electron microscopy (EM). Virus
stocks were serially diluted in MEM, adsorbed onto confluent Vero
E6 cells in 12-well dishes, incubated for 1 h at 377C, and covered
with an agarose overlay [16]. A 1:5000 dilution of neutral red in
buffered saline solution was added 6 days later, and plaques were
counted the following day. EBO virions were also directly enumerated by EM [17]. Virus preparations were mixed with a suspension
of 200-nm polystyrene spheres (Duke Scientific, Palo Alto, CA)
at a final concentration of 2.15 1 108 spheres/mL. Aliquots (5 mL)
of the virus-sphere mixture were applied to 300-mesh nickel grids,
which were precoated with formvar and carbon, and glow-discharged. After drying, the grids were immersed sequentially in 1%
glutaraldehyde in PBS, PBS alone, osmium tetroxide, and distilled
water. They were then treated with uranyl acetate and examined
at 80 kV with a transmission electron microscope (1200 EX; JEOL,
Peabody, MA). All virions and spheres were counted in a total of
100 grid squares, and the virus titer was calculated.
Serial passage of EBO virus in mice. Newborn litters of
BALB/c mice and adult female BALB/c, C57BL/6, and ICR (CD1) mice were obtained from the National Cancer Institute, Frederick, MD. Serial passage was initiated by inoculating litters of 2day-old suckling BALB/c mice ip with EBO-Z ’76 Mp3 Vp2.
Eight days later, the litters were killed, and livers and spleens were
removed aseptically and pooled. They were then ground in a mortar
with sterile sand and growth medium, and the suspension was
clarified by low-speed centrifugation and titrated. In passages two
through eight, the pooled liver suspension was inoculated subcutaneously (sc) into new litters, and the process was repeated. Animals
were killed 8–10 days after inoculation. Passage 2 was carried
out in 2-day-old, passages 3–6 were carried out in 4-day-old,
passages 7 and 8 were carried out in 8-day-old, and passage 9 was
carried out in 15-day-old mice. Mice at each passage level were
inoculated with .02 mL of undiluted liver suspension, which ranged
in titer from 200 to 5 1 106 pfu/mL. Some ninth-passage mice
were inoculated sc and some ip.
Plaque purification. Vero E6 cells were infected with diluted
liver suspension from the ninth mouse passage and covered with
an agarose overlay. After staining with neutral red, 11 single
plaques were removed by pipette, suspended by freeze-thawing
and vortexing, and used to infect flasks of Vero E6 cells. Once
generalized cytopathic effect was observed, the supernatants were
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collected, and a 100-fold dilution of each was inoculated ip into
groups of 3-week-old mice. The supernatant that caused 100%
mortality in the shortest time period was diluted for another round
of plaque purification, and a 100-pfu dose of each of 8 stocks
derived from second-round plaques was tested in mice. The most
virulent isolate (EBO-Z ’76 Mp3 Vp2 Mp9 GH) was amplified,
stored as aliquots, and used in all subsequent experiments.
Evaluation of lethality and viral replication in mice. Lethality
was determined by diluting EBO-Z virus in growth medium and
inoculating it ip, sc, or ic in suckling mice or ip, sc, intradermally
(id), or intramuscularly (im) in adult mice. The LD50 dose of
mouse-adapted EBO-Z ’76 Mp3 Vp2 Mp9 GH inoculated ip into
adult BALB/c mice was determined by inoculating groups of 6–
10 mice with serial 10-fold dilutions of virus in 3 separate experiments and analyzing the combined results by use of a linear regression program (SPSS, Chicago). In one experiment, groups of 16week-old mice were anesthetized and exsanguinated at daily intervals after ip infection with 100 pfu of mouse-adapted virus, the
serum was collected, and the livers and spleens were removed
aseptically. The virus titers of the serum and of a weighed portion
of each organ were determined as described above, and the remainder was preserved for microscopy study. In another experiment,
the same procedure was performed 4 days after ip inoculation of
100 pfu of EBO-Z ’76 Vp2, EBO-Z ’76 Mp3 Vp2, or mouseadapted virus EBO-Z ’76 Mp3 Vp2 Mp9 GH.
Histology, immunohistochemistry, and EM. Portions of liver
and spleen were immersion-fixed for 30 days in 10% neutralbuffered formalin and then embedded in paraffin. Sections were
mounted on glass slides and stained with hematoxylin and eosin;
replicate sections were stained immunohistochemically. In brief,
sections were treated with a 0.05% solution of Protease VIII
(Sigma, St Louis) for 3 min at 377C, blocked at room temperature
with normal goat serum for 20 min, and incubated for 1 h with
rabbit anti-EBO serum diluted 1:500 with 1% powdered milk in
PBS. Sections were incubated for 30 min each with biotinylated
goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA) and
alkaline phosphatase-labeled streptavidin (Life Technologies
Gibco BRL, Gaithersburg, MD). Slides were placed in naphthol
AS-BI phosphate/hexazotized new fuchsin (Kirkegaard & Perry,
Gaithersburg, MD) for color development and counterstained with
Mayer’s hematoxylin.
Necropsy tissues from EBO-infected monkeys served as positive
controls. Liver and spleen from uninfected mice and the substitution of normal rabbit serum for rabbit anti-EBO serum served as
negative controls. Small fragments of tissue for EM were immersion fixed for 1 h in 2% glutaraldehyde in 0.1 M Millonig’s phosphate buffer (pH 7.4), rinsed in buffer, and postfixed for 1–2 h in
1% osmium tetroxide in buffer. The material was then rinsed,
stained with 0.5% uranyl acetate in ethanol, dehydrated in ethanol
and propylene oxide, and embedded in POLY/BED 812 resin
(Polysciences, Warrington, PA) for sectioning [15].
Neutralization of virus with antiserum. Aliquots of EBO virus
in growth medium were mixed with serial dilutions of a commercially acquired purified preparation of IgG from horses hyperimmunized with EBO-Z (equine IgG; Epidbiomed, Novosibirsk, Russia; provided by Peter Jahrling [5, 18, 19]) and incubated at 347C
for 1 h. Controls consisted of virus mixed with immune serum
from guinea pigs that had survived infection with Marburg (MBG)
Musoke virus (provided by Alan Schmaljohn, USAMRIID) or with
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normal serum or medium alone. For in vitro plaque-reduction tests,
the mixture was used to infect Vero E6 cells, and plaques were
counted 1 week later. For in vivo assessment of lethality for mice,
the mixture was inoculated ip into adult BALB/c mice, which were
monitored for survival.
Immunization and challenge. Adult mice were inoculated ip
with 1–1000 pfu of EBO-Z ’76 Vp2, EBO-Z ’76 Mp3 Vp2, or
EBO-Z ’95 Vp3, or with plaque-purified MBG Musoke virus or
MBG Ravn virus (provided by Alan Schmaljohn) or medium alone.
In one experiment, aliquots of EBO-Z ’95 Vp3 equivalent to 100
pfu/dose were inactivated by heating at 757C for 30 min or by
gamma-irradiation with 6 MR from a 60Co source prior to ip inoculation. These samples showed no residual infectivity for Vero E6
cells. In other experiments, mice were inoculated sc, id, or im with
mouse-adapted EBO-Z virus and then challenged 3 weeks later by
ip injection of 100 pfu of the same virus.
Reverse transcriptase–polymerase chain reaction (PCR) and
nucleotide sequence analysis. Total cellular RNA was isolated
from one 25-cm2 flask each of Vero E6 cells infected with EBOZ ’76 Mp3 Vp2 or EBO-Z ’76 Mp3 Vp2 Mp9 GH virus 4 days
after infection, by using Trizol reagent (Life Technologies Gibco
BRL). The RNA pellet was resuspended in 10 mL of RNase-free
water and heated at 607C for 10 min; a 2-mL aliquot was then
used for first-strand cDNA synthesis using a Superscript kit (Life
Technologies Gibco BRL) and random hexamer primers. PCR
amplification with the Expand High Fidelity kit (Boehringer
Mannheim, Indianapolis) used the forward primer 5*-GATCAGATCTACAATGGGCGTTACAGG-3* and the reverse primer
5*-GATCAGATCTCTAAAAGACAAATTTG-3*, which amplify
nucleotides corresponding to positions 6037–8070 with respect
to the genome of the 1976 Mayinga strain of EBO-Z (GenBank
accession number L11365) [20, 21]. PCR amplification was done
in 100-mL volumes, using a PCR 9600 thermocycler (Perkin-Elmer, Foster City, CA). Forty cycles (each consisting of 947C for
40 s, 387C for 45 s, and 727C for 1 min) were followed by 1 cycle
of 727C for 5 min. PCR products were cloned into the pCRII
vector (Stratagene, La Jolla, CA), and large-scale preparations
were made by using purification columns (Qiagen, Chatsworth,
CA). Nucleotide sequences were determined by the dideoxy chaintermination method, with a Sequenase 2.0 kit (United States Biochemicals, Gaithersburg, MD).

Results
Serial mouse passage. Non – mouse-adapted viruses EBOZ ’76 Vp2 and EBO-Z ’76 Mp3 Vp2 were lethal for many or
all 4-day-old suckling BALB/c mice when inoculated ip or ic,
but they did not cause illness in 8- or 15-day-old mice (data
not shown). Serial passage was therefore begun in young suckling mice. In the first passage, EBO-Z ’76 Mp3 Vp2, which
had previously been passed 3 times in suckling mice inoculated
ic, was injected ip in 2-day-old mice. About 103 pfu of virus
in pooled liver suspension recovered from these animals was
then injected sc into 2-day-old mice, producing illness (ruffled
fur and diminished activity) or death in several mice before
exsanguination of the remaining animals at day 9 after infection. The livers and spleens of these second-passage mice each
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yielded a total of 104 – 105 pfu of virus, demonstrating that sc
inoculation resulted in systemic infection. Passage was continued in 4-day-old mice, with similar results.
After 6 passages, the virus caused illness in 8-day-old mice,
1 of which died before the remainder were killed at day 10.
In the eighth passage, the virus was lethal for 5 of 16 8-dayold mice before the remainder were killed on day 9. Routine
titration of liver suspension recovered from eighth-passage
mice revealed a mixture of plaque phenotypes of the virus on
Vero E6 cells: In addition to pale, moderately well-defined
‘‘bull’s eye’’ plaques, which had been seen up to that point, a
new population of similarly sized but sharply outlined, transparent plaques was also present. Vero E6 cells infected with
this material showed typical replicating EBO virus by EM. No
other infectious agent was observed. This virus and those from
all previous passages were neutralized in vitro by equine IgG
raised against EBO-Z [5, 18, 19], confirming that all isolates
consisted of EBO virus (data not shown). Passage 8 liver suspension did not produce visible illness when tested in sc-inoculated 15-day-old mice, but ip inoculation was lethal for 14 of
18 mice.
Liver suspension from a moribund ninth-passage mouse
yielded a pure population of clear plaque virus. Virus derived
from a single clear plaque (plaque G) caused 100% mortality
in 6 days when inoculated ip in 3-week-old mice, as did virus
isolated in a second round of plaque purification (plaque GH).
This doubly plaque-purified ninth-passage virus, designated
EBO-Z ’76 Mp3 Vp2 Mp9 GH or mouse-adapted virus, was
used in all subsequent experiments.
Lethality for suckling and adult mice. Mouse-adapted virus
inoculated ip or ic was uniformly lethal for 8- and 15-day-old
mice. The same virus inoculated sc was lethal for 8-day-old
animals, but killed less than half of the 15-day-old sucklings
and did not cause visible illness in 3-week-old mice. An ip
dose of 100 pfu of mouse-adapted virus was lethal for 5-weekold BALB/c, C57BL/6, and ICR (CD-1) mice (figure 1). Additional studies with smaller quantities of virus showed that
BALB/c and CD-1 mice did not differ in their susceptibility
to the virus. Mouse-adapted virus was lethal for BALB/c mice
ranging in age from 5 to 16 weeks. The LD50 fell within the
range of 0.025 – .04 Vero E6 pfu (i.e., a dose of 1 pfu was
equivalent to Ç30 LD50). Direct counting by EM of virions
mixed with a known concentration of microspheres revealed
that 1 pfu was equivalent to 25 – 30 virions (figure 2). Therefore,
1 LD50 equaled roughly 1 virion. Titration of a stock of the
1995 strain of EBO-Z virus by EM gave a similar ratio of
virions to plaque-forming units.
EBO disease in adult mice. In a series of experiments,
mice developed ruffled fur, showed progressive slowing of
activity, and began to lose weight 3 days after ip injection of
1 or 100 pfu (30 or 3000 LD50) of mouse-adapted virus (figure
3A). The smaller dose of virus caused a slightly less precipitous
onset of disease and weight loss, but the rate of weight loss,
once it commenced, was about the same for the 2 doses. A
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Figure 1. Mouse-adapted Ebola virus, subtype Zaire (EBO-Z), was
lethal for 3 strains of mice. Groups of 8 5-week-old ICR (CD-1)
outbred and BALB/c and C57BL/6 inbred female mice were inoculated intraperitoneally with 100 pfu (3000 LD50) of EBO-Z ’76 Mp3
Vp2 Mp9 GH virus and monitored for survival. All mice became ill
within 3 – 4 days after injection. Further studies with smaller doses
of virus showed no difference in susceptibility between CD-1 and
BALB/c mice.

similar pattern of acute onset of weight loss has been observed
in EBO-infected guinea pigs [11]. Averaged over 8 experiments
each, the mean time to death of 98 mice inoculated with 30
LD50 was 6.9 days, and that of 78 mice inoculated with 3000
LD50 was 5.8 days. In various experiments, a small number of
animals bled spontaneously from the orbit, bladder, gastrointestinal tract, or within the abdominal cavity before death. Two
mice showed thrombosis of the hepatic portal veins and infarcts
in the liver at necropsy. Blood collected in the last 1 – 2 days
of illness failed to clot, indicating the presence of a coagulation
defect, the nature of which has not yet been determined.
To study in vivo viral replication and organ pathology, we
inoculated a group of 16-week-old mice ip with 100 pfu (3000
LD50) of mouse-adapted virus; 1 – 3 animals were killed each
day. Virus titers in the liver and spleen exceeded 107 pfu/g on
the second day and then increased more slowly, reaching a
maximum of ú109 pfu/g in both organs of the only surviving
mouse on the fifth postinoculation day (figure 3B). The mean
serum virus titer peaked on the third day at 7.5 1 107 pfu/mL.
We compared the replication of non – mouse-adapted and
mouse-adapted EBO viruses in adult mice by inoculating animals ip with 100 pfu of EBO-Z ’76 Vp2, EBO-Z ’76 Mp3
Vp2, or EBO-Z ’76 Mp3 Vp2 Mp9 GH and killing them 4
days later. In the 2 groups inoculated with non-adapted virus,
the virus titers in the spleen ranged from 1.6 1 104 to 1.2 1
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105 pfu/g (figure 4), roughly 3 1 103 to 2 1 104 pfu per spleen.
Similarly, virus titers in the liver indicated a total of Ç4 1
103 to 1.5 1 104 pfu/organ (not shown). The combined quantity
of virus in each animal’s liver and spleen ranged from Ç8 1
103 to 3 1 104 pfu, a larger quantity than had been inoculated,
giving evidence of viral replication. By contrast, the spleens
of mice inoculated with mouse-adapted EBO-Z yielded a mean
of 6.2 1 107 pfu/g, ú1000 times greater than the mean titer
of EBO-Z ’76 Vp2 or EBO-Z ’76 Mp3 Vp2 at the same time
point. A comparable disparity in titers was observed in the
liver.
Histology, immunohistochemistry, and ultrastructure in liver
and spleen. Two days after ip inoculation of 100 pfu (3000
LD50) of mouse-adapted EBO-Z, the liver appeared essentially
normal upon routine light microscopy, but EBO virus antigen
was detected in sinusoidal lining cells, consistent with Kupffer’s
cells, by immunohistochemistry (not shown). By day 4, the liver
had developed disseminated, often coalescing, foci of hepatocellular vacuolar change, degeneration, and necrosis (figure 5A).
Hepatocytes and, less frequently, Kupffer’s cells contained large
(3–15 mm), pleomorphic, acidophilic, cytoplasmic viral inclusions. The sinusoids contained necrotic cellular debris and small

Figure 2. Ebola virus particle and polystyrene sphere used for
counting virions. Preparation negatively contrasted with 1% uranyl
acetate. Bar Å 615 nm.
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Figure 3. A, BALB/c mice infected with mouse-adapted Ebola virus, subtype Zaire, begin to lose weight 3 days after inoculation. Eight
groups of 6 – 15 mice (5 – 16 weeks old) were injected intraperitoneally (ip) with 1 pfu (30 LD50 ; 5 groups, open symbols) or 100 pfu (3000
LD50 ; 3 groups, solid symbols) of mouse-adapted Ebola virus, and their mean weight was determined daily. All mice were dead by day 7
after infection. B, Virus titers in spleen, liver, and serum increased rapidly after ip infection. A group of 16-week-old female BALB/c mice
was inoculated ip with 100 pfu (3000 LD50) of mouse-adapted virus. One animal was killed on day 1, 2 were killed on day 2, 3 each were
killed on days 3 and 4, and only survivor was killed on day 5. Virus titers in serum (pfu/mL) and liver and spleen (pfu/g) were determined.
Mean and range values (bars) are shown.

Figure 4. Mouse-adapted Ebola virus, subtype Zaire (EBO-Z), replicated to higher titers than non-adapted EBO-Z viruses in spleens
of adult mice. Five-week-old female BALB/c mice were inoculated
intraperitoneally with 100 pfu of EBO-Z ’76 Vp2 (6 mice), EBO-Z
’76 Mp3 Vp2 (6 mice), or EBO-Z ’76 Mp3 Vp2 Mp9 GH (3 mice).
Four days later, animals were killed, blood and tissue were collected,
and virus titers in serum, spleen, and liver were determined. Titers
in spleen are shown.
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numbers of neutrophils and monocytes. Kupffer’s cells, sinusoidal endothelial cells, and hepatocytes within and adjacent to
areas of hepatocellular degeneration and necrosis were immunoreactive for EBO virus antigen (figure 5B).
Antigen was also present in circulating monocytes (not
shown). Cell-free and cellular debris – associated immunoreactive material was present in the sinusoids. Characteristic EBO
virus inclusions and budding virions were observed in hepatocytes, Kupffer’s cells, and sinusoidal endothelial cells by EM
(figure 6). Large numbers of free virions were present in the
sinusoids and Disse’s spaces. In the spleen, EBO virus antigen
was detected by immunohistochemistry in numerous large
mononuclear cells in marginal zones 2 days after infection
(figure 5C). Ultrastructural examination showed replicating
EBO virus in marginal zone macrophages and in macrophages
of the splenic white pulp but not in lymphocytes. Infrequent
small deposits of fibrin were observed in the red pulp late in
the course of infection.
Neutralization of virus by antiserum. The 50% plaque-reduction neutralization titer of equine IgG against mouseadapted EBO-Z was 1:6400, which was equal to its titer against
EBO-Z ’76 Vp2 and differing õ2-fold from titers against EBOZ Mp3 Vp2 and EBO-Z ’95 Vp3. Preincubation of mouseadapted virus with equine IgG blocked its lethality for mice.
A challenge dose of 30 LD50 was neutralized by a 1:50 or
1:500 dilution of IgG, while a 1:5000 dilution of IgG or various
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Figure 5. Histopathology of liver and spleen of 16-week-old
BALB/c mice infected intraperitoneally with 100 pfu (3000 LD50) of
mouse-adapted Ebola virus, subtype Zaire. A, Hepatocytes show foci
of vacuolation, degenerative changes, and necrosis 4 days after infection (hematoxylin and eosin staining). Some cells contain acidophilic
viral inclusions (arrow, center). B, Immunostaining of same tissue
with rabbit anti-Ebola serum reveals viral antigen in sinusoidal lining
cells, consistent with Kupffer’s cells or endothelial cells (or both),
and in clusters of hepatocytes. C, Immunostaining of spleen sections
from second day after infection shows viral antigen in marginal zone
cells, consistent with macrophages and dendritic cells.
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Figure 6. Thin section through hepatic sinusoid of 3-week-old mouse 5 days after infection with mouse-adapted Ebola (EBO) virus, subtype
Zaire. Characteristic EBO virus inclusions (*) are present in hepatocytes (H), Kupffer’s cells (K), and sinusoidal endothelial lining cell (E).
EBO virions are seen budding from Kupffer’s cells into lumen of sinusoid (S). Space of Disse’s (D) is congested with EBO virus particles.
Bar Å 2.5 mm.
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passage, EZ ’76 Mp3 Vp2, and of the mouse-adapted virus,
EZ ’76 Mp3 Vp2 Mp9 GH, and compared them to the GenBank
sequence of the GP gene of the Mayinga strain of EBO-Z
virus. The starting stock and the mouse-adapted virus differed
identically from the GenBank sequence at the following 3 positions, listed with the GenBank nucleotide first: 6232 AúG,
6775 TúC, and 7670 TúC. These nucleotide differences
would result in the following amino acid changes, with the
amino acid predicted by GenBank sequence listed first: SúP,
SúP, and IúT, respectively. The nucleotide sequence of EZ
’76 Mp3 Vp2 also differed from the GenBank sequence at the
following 3 positions, with the GenBank nucleotide listed first:
6165 AúG, 6909 CúT, and 7212 AúC. The sequence of the
mouse-adapted virus was the same as the GenBank sequence
at these sites. These 3 nucleotides form the third bases of
codons, and the differences are not predicted to result in amino
acid changes.

Discussion
Figure 7. IgG from horses immunized with Ebola virus, subtype
Zaire (EBO-Z) neutralizes mouse-adapted EBO-Z virus. Mice were
inoculated intraperitoneally with 30 LD50 of mouse-adapted virus
preincubated with various dilutions of equine IgG or with control
sera. A 1:50 or 1:500 dilution of IgG neutralized virus, so mice neither
became ill nor died. 1:5000 dilution of IgG, 1:20 or 1:200 dilution
of guinea pig anti-Marburg serum, 1:20 dilution of normal mouse
serum, and growth medium alone failed to protect mice (results for
groups partially overlap).

dilutions of anti-MBG serum or normal serum failed to protect
against lethal infection (figure 7).
Immunization and challenge. Adult mice inoculated ip
with 100 pfu of EBO-Z ’76 Vp2 or with doses of 1 – 1000 pfu
of EBO-Z ’95 Vp3 showed no visible illness. When challenged
ip 3 weeks later with 100 pfu (3000 LD50) of mouse-adapted
virus, all mice survived without any sign of disease (data not
shown). However, mice that were inoculated ip with a quantity
of EBO-Z ’95 Vp3 equivalent to 100 pfu, which had been
inactivated by heat or by gamma irradiation before injection,
were not protected against subsequent challenge with the same
dose of virus. ip inoculation of MBG virus did not cause visible
illness and did not cross-protect against subsequent challenge
with mouse-adapted EBO-Z.
Mouse-adapted EBO-Z virus caused illness in adult mice
only when injected into the peritoneal cavity. sc inoculation of
as much as 106 pfu of mouse-adapted virus did not cause visible
illness or death in adult mice (not shown). In one experiment,
sc, im, or id inoculation of 100 pfu of mouse-adapted virus
did not cause illness in mice, with the exception of 1 animal
that died 6 days after id inoculation (figure 8). The mice in
that experiment were shown to be immune when challenged
ip 3 weeks later with 100 pfu (3000 LD50) of the same virus.
Sequence of the glycoprotein (GP) gene. We determined
the sequence of the GP gene of our starting virus for serial
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Serial passage of the 1976 strain of EBO-Z virus in suckling
mice resulted in the emergence of an agent with a novel dual
phenotype: clear plaque morphology on Vero E6 cells and

Figure 8. Peripheral inoculation of mouse-adapted Ebola virus,
subtype Zaire, protects against subsequent lethal intraperitoneal (ip)
challenge with same virus. Six-week-old female BALB/c mice were
either inoculated with 100 pfu of mouse-adapted virus subcutaneously
(sc) in upper back or at base of tail, intramuscularly (im) in quadriceps
muscle, intradermally (id) in mid-back, or ip, or they were left untreated. All mice inoculated ip and 1 mouse injected id died, while
rest remained healthy. Three weeks later, all surviving mice were
challenged ip with 100 pfu (3000 LD50) of same virus. All previously
inoculated mice remained healthy.
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lethality for adult mice. A series of experiments confirmed that
the clear plaque agent was EBO virus rather than a contaminant
and that EBO virus caused the illness and death of adult mice.
Examination of a suspension of purified mouse-adapted virus
by EM showed typical EBO virions. Assay of these particles
demonstrated that lethality depended predictably on inoculation
of virus: a dose of Ç3 virions (3 LD50) killed 18 of 20 mice,
while one-tenth of that dose caused 2 deaths in 20 mice. Inoculating this suspension into mice resulted in the appearance of
characteristic replicating EBO virus in the liver and spleen.
The virus titer in these organs reached 108 pfu/g by the third
day after inoculation, coinciding with the onset of illness, and
continued to increase until death.
As further evidence that lethal infection of mice was caused
by EBO-Z, we found that the in vitro and in vivo infectivity
of the virus suspension was neutralized by IgG from horses
hyperimmunized against EBO-Z and that mice previously inoculated with the 1976 or 1995 strains of EBO-Z virus were
protected against challenge with the agent.
The EBO mouse model has highly desirable features for an
animal model of an exceptionally virulent human disease. The
entire course of illness is played out in a week or less: All
mice become acutely ill 3 days after infection, similar to the
rapid onset of disease in primates, and die 5 – 8 days after
challenge. The mouse-adapted agent is fatal for BALB/c mice
over a broad age range. The use of purified, aliquotted virus
and genetically identical mice of the same sex and similar
age yields virtually uniform results. Such reproducibility will
facilitate statistical evaluation of the effect of prophylactic or
therapeutic interventions.
We initially suspected that the changes in plaque phenotype
and virulence that occurred during serial passage resulted from
mutations in the GP gene, which is involved in virus binding
to cellular receptors and entry into cells [22]. However, we
found that the predicted peptide sequences of the GP of the
pre- and postpassage viruses were identical: Although there
were 3 nucleotide differences between the GP sequence of the
starting stock and that of the mouse-adapted virus, none of the
differences was predicted to result in an amino acid change. It
thus appears that accelerated replication of the adapted virus
in mice resulted from an alteration in events subsequent to
virus entry into cells, which was brought about by a change in
a viral protein other than GP.
A prominent feature of lethal EBO infection in mice is the
involvement of multiple cell types, similar to the pattern of
infection in guinea pigs and primates [6 – 8, 10, 11, 14]. In
the livers, we observed viral replication in Kupffer’s cells,
hepatocytes, and endothelial cells, leading to disseminated,
multifocal necrosis, which resembled pathology in other animal
models. The spleens of mice, guinea pigs, and primates showed
a similar immunohistochemical localization of EBO virus antigen in cells of the MPS system. However, we noted few fibrin
deposits in the spleens of moribund mice, while fibrin was
more prominent in the spleens of guinea pigs, and copious
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deposits were observed throughout the red pulp of the spleens
of nonhuman primates dying of EBO infection [8]. Despite the
paucity of fibrin deposition, EBO-infected mice showed other
signs of coagulation abnormalities, including occasional spontaneous bleeding from external and internal sites. More detailed
findings from a larger time-course study of EBO-Z in mice
will be presented in a later report.
Another notable characteristic of EBO disease in mice is the
rapidity of virus proliferation. Mouse-adapted EBO-Z replicated in the liver and spleen to titers ú108 pfu/g within 3
days after infection, eventually reaching 109 pfu/g. These titers
exceed reported peak concentrations in the liver and spleen of
monkeys (ú107 pfu/g) and guinea pigs (ú106 pfu/g) [11]. Peak
viremia in mice (ú107 pfu/mL) was comparable to maximum
titers observed in monkeys (106 – 107 pfu/mL) but exceeded
those in guinea pigs (ú105 pfu/mL) [2, 11, 23]. Virus titers
were higher in the spleen than in the liver or serum, as has
been observed in guinea pigs [11].
An interesting feature of the EBO mouse model is the disparity between the results of ip and peripheral inoculation.
The agent was highly infectious when injected ip: the LD50
equaled a single EBO virion. In contrast, mice injected sc
with doses as large as 106 pfu of the same virus did not
become ill. This phenomenon is not observed in guinea pigs
or nonhuman primates, which are susceptible to EBO or MBG
virus inoculated sc, im, or ip. On the basis of these other
animal models, there is no reason to believe that peripherally
inoculated EBO virus simply remains sequestered at the injection site in mice rather than entering lymphatic vessels and
reaching regional lymph nodes. In fact, we found evidence
that virus inoculated sc, id, or im was taken up by or infected
(or both) antigen-presenting cells of the MPS system before
or after entry into regional lymph nodes, as mice developed
a protective immune response and were protected against subsequent ip challenge.
Viral replication in lymph nodes draining an injection site
has been observed after sc inoculation of EBO-Z in guinea
pigs [11]. However, it appears that either the corresponding
cells in mice were refractory to virus replication or that an
infection that began in regional lymph nodes was rapidly eliminated through immune mechanisms. We have not determined
whether systemic dissemination of peripherally inoculated virus takes place.
Virions delivered into the peritoneal cavity are distributed
very differently from those injected into the soft tissues. Material
inoculated ip passes rapidly through peritoneal lymphatic vessels
and enters the bloodstream; even red blood cells make this transit
within minutes after injection [24]. Virions inoculated ip may
thus reach the bloodstream and initially infect MPS cells in
the liver and spleen. Mouse-adapted virus clearly infected these
organs soon after ip inoculation, since titers in the liver and
spleen already exceed 107 pfu/g 2 days after infection. In marked
contrast to the failure of peripherally inoculated virus to cause
systemic infection, it appears that the arrival of even a few
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virions of mouse-adapted EBO-Z in the liver or spleen leads to
rapid viral proliferation. This may result either from the presence
of a permissive host cell or from a weakness in protective immune mechanisms. Alternatively, some virus inoculated ip may
infect peritoneal macrophages, many of which would pass
through diaphragmatic lymphatics and enter mediastinal lymph
nodes [25], leading to viral proliferation.
We were able to detect replication of non – mouse-adapted
EBO-Z ’76 Vp2 and EBO-Z Mp3 Vp2 viruses in the liver and
spleen of adult mice, but the yield was exceeded ú1000-fold
by that of mouse-adapted virus under the same conditions.
Thus, non-adapted and adapted EBO viruses may share the
same initial target cells, but the former viruses replicate slowly
after infection, apparently giving the animal sufficient time to
eliminate virus-infected cells through non-specific or specific
(or both) immune mechanisms. Mouse-adapted virus, on the
other hand, may simply proliferate too rapidly for the infection
to be suppressed.
ip inoculation of as little as 1 pfu of the 1995 strain of non–
mouse-adapted EBO-Z was sufficient to elicit a protective immune response in mice, enabling them to survive a subsequent
3000 LD50 challenge. However, the same dose of heat- or radiation-inactivated virus did not induce immunity. These findings
indicate that viral replication was required for inoculation of a
very small quantity of virus to result in protective immunity.
We have not yet determined whether such protection is based
on a humoral or a cell-mediated immune response, nor have
we attempted to use larger amounts of inactivated EBO-Z to
immunize mice, as has been used in guinea pigs [26].
The use of wild-type EBO-Z to vaccinate mice has no
equivalent in primate models of EBO infection, but the results
at least demonstrate that it is possible to obtain solid protection against an otherwise lethal virus. Our findings suggest
that the mouse model could be used for the initial evaluation
of EBO virus vaccines. We do not know whether results obtained with the mouse model will accurately predict the efficacy of the same measures in primates. The predictive value
of vaccination experiments will be affected by differences in
the pathogenesis of EBO infection in mice and primates and
by variations in their immune responses to the same antigens.
Similarly, differences in drug metabolism between mice and
primates might limit the model’s accuracy in predicting the
efficacy of antiviral agents in treating human EBO cases.
However, we are optimistic that this new animal model of
EBO infection will contribute significantly to the effort to
control this deadly emerging pathogen. The mouse model
may also prove valuable as a tool of basic research, as the
availability of immunologically characterized inbred strains
and of transgenic and knockout mice may make it possible
to design experiments that will help to elucidate the pathophysiology of EBO hemorrhagic fever.
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